The Pharmaceutical Benefits Advisory Committee recommended that PrEP be listed on the Pharmaceutical Benefits Scheme (PBS) in Australia. The implementation of the recommendation is expected to take few months and to be finalized by the end of June. For more information, click here.
- HIV drug PrEP wins taxpayer subsidy marking milestone in decades-long battle against AIDS
- HIV researchers welcome recommendation to list PrEP on PBS
- ‘HIV has nowhere to go now’: Breakthrough drug PrEP to be approved for public subsidy
PHARMAC announced that from 1 March 2018 PreP will be publicly funded in New Zealand. To read the full announcement, click here.
Further reading related to PrEP: